跳至主要内容
临床试验/EUCTR2012-001419-21-DE
EUCTR2012-001419-21-DE
进行中(未招募)
1 期

An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection - CHAT Study

niversitätsklinikum Bonn0 个研究点目标入组 40 人2013年4月9日
相关药物Incivo

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
niversitätsklinikum Bonn
入组人数
40
状态
进行中(未招募)
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2013年4月9日
结束日期
待定
最后更新
4年前
研究类型
Interventional clinical trial of medicinal product
性别
Male

研究者

发起方
niversitätsklinikum Bonn

入排标准

入选标准

  • 1\. Documented current acute hepatitis C genotype 1 infection with detectable HCV\-RNA (PCR\-assay) with an estimated duration less than 24 weeks as defined below: a. First HCV RNA positive AND b. Prior negative anti\-HCV antibody or HCV RNA test within 6 months OR c. rise of liver transaminases above 2\.5 x ULN within the past 6 months with prior normal transaminases during the year before AND d. exclusion of other causes of acute hepatitis
  • 2\. Confirmed HIV infection
  • 3\. Receiving a atazanavir\-, etravirine\-, rilpivirine\-, efavirenz\- or raltegravir\-based ART regimen or able to switch regimen to these agents with an undetectable HIV viral load for at least 3 months, or not receiving ART with no immediate plans to start ART during the first 6 months of study 4\. CD4 T cell count \>200/ìl at screening in patients under ART, CD4 T cell count \>500/ìl at screening in patients without ART
  • 5\. Patients who are 18 years or older
  • 6\. Able to give informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 38
  • F.1\.3 Elderly (\>\=65 years) yes

排除标准

  • 1\. HCV infection with non\-1 genotype
  • 2\. Acute opportunistic infection requiring treatment
  • 3\. Malignancy requiring chemotherapy or radiotherapy
  • 4\. Active HBV infection (HBs Ag \+ with positive hepatitis B DNA unless tenofovir containing ART)
  • 5\. Known autoimmune disease
  • 6\. Hepatic failure
  • 7\. History of ischaemic heart disease or other serious cardiac disease
  • 8\. Current symptoms of depression, or past history of depression for which the patient is currently taking medication, or history of other serious psychiatric disease
  • 9\. Haemoglobinopathy or severe anaemia of any cause
  • 10\. Serious abnormality on screening blood tests including, but not limited to: Hemoglobin \<8g/dl, absolute neutrophil count \<750/mm3, platelets \<50000/mm3, creatinine clearance \<60ml/min

结局指标

主要结局

未指定

相似试验

招募中
4 期
A Randomized, Open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy - a strategy trialChemotherapy-induced polyneuropathynerve pain10034606
NL-OMON52883eids Universitair Medisch Centrum110
进行中(未招募)
1 期
A Randomized, open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy – A strategy trial
EUCTR2020-001285-11-NLeiden University Medical Center100
已完成
2 期
Buffered bicarbonate solutions for liver transplantatioiver transplantationLiver transplantationSurgery - Other surgeryOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12619001227189Professor Rinaldo Bellomo52
进行中(未招募)
1 期
Clinical study aimed to compare tocilizumab to anti-TNF treatment and to discover biomarkers for treatment selection in rheumatoid arthritis patients with inadequate response to a first anti-TNFRHEUMATOID ARTHRITISMedDRA version: 20.0Level: LLTClassification code 10037738Term: R arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: LLTClassification code 10039014Term: Rh arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 23.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2016-001987-12-ITSOCIETA' ITALIANA DI REUMATOLOGIA - SIR208
招募中
3 期
A study to examine whether giving steroids in low dose daily is more effective than if given on alternate days, in controlling disease activity in patients with frequently relapsing nephrotic syndrome
CTRI/2019/01/017091Indian Council of Medical Research